Hualan Bio Executives Suspected Of Insider Trading
This article was originally published in PharmAsia News
Executive SummaryAfter Hualan Biological's share price rose following SFDA approval of the company's hepatitis B vaccine, some company executives are now suspected of insider trading
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.